Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

319
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
319
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

415
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
415
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

464
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
464
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

953
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
953

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional profiling of male mouse muscle across aging stages: a gene ontology analysis of the muscle matreotype.

BMC genomics·2026
Same author

First experience in employing a complex digital support system accompanied by personal assistance to improve aftercare in patients with stroke or transient ischemic attack - results of the PostStroke-Manager feasibility study.

Scientific reports·2025
Same author

The PostStroke-Manager - combining mobile, digital and sensor-based technology with personal assistance: protocol of the feasibility study.

Neurological research and practice·2021
Same author

An Automatic Method for the Segmentation and Classification of Imminent Labor Contraction From Electrohysterograms.

IEEE transactions on bio-medical engineering·2019
Same author

COMPARISON OF PLASMA PHENYLALANINE DETERMINATION BY DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS AND BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY IN RELATION WITH THE SCREENING OF PHENYLKETONURIA.

Acta endocrinologica (Bucharest, Romania : 2005)·2019
Same author

PLASMA PHENYLALANINE DETERMINATION BY QUANTITATIVE DENSITOMETRY OF THIN LAYER CHROMATOGRAMS AND BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY IN RELATION WITH MODERN MANAGEMENT OF PHENYLKETONURIA.

Acta endocrinologica (Bucharest, Romania : 2005)·2019

Related Experiment Video

Updated: Apr 15, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.6K

A Model-Based Pharmacokinetics Characterization Method of Engineered Nanoparticles for Pilot Studies.

Jean-Baptiste Tylcz, T Bastogne, H Benachour

    IEEE Transactions on Nanobioscience
    |April 4, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This study introduces a new model-based method for characterizing nanomaterial pharmacokinetics in vivo. It enables rapid selection of relevant models and optimization of study protocols, aiding nanomedicine development.

    More Related Videos

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.3K
    Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
    09:41

    Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

    Published on: February 25, 2021

    25.9K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.6K
    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.3K
    Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
    09:41

    Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

    Published on: February 25, 2021

    25.9K

    Area of Science:

    • Biomedical Engineering
    • Nanomedicine
    • Pharmacokinetics

    Background:

    • Engineered multifunctional nanomaterials offer promise in oncology but require robust biological characterization methods for quality and safety assessment.
    • Current methods for evaluating nanomaterial behavior in vivo are often time-consuming and may not be optimal for early-stage research.
    • Developing efficient preclinical assessment tools is crucial for advancing nanomedicine applications in cancer therapy.

    Purpose of the Study:

    • To propose and exemplify a novel model-based approach for the pre-characterization of multifunctional nanomaterial pharmacokinetics using small-scale in vivo studies.
    • To demonstrate the utility of this method in rapidly selecting appropriate pharmacokinetic (PK) models and refining in vivo experimental protocols.
    • To assess the potential of the approach in providing preliminary information on tumor uptake, elimination rates, and residual storage of nanomaterials.

    Main Methods:

    • Integration of magnetic resonance imaging (MRI) image processing, continuous-time system identification algorithms, and statistical analysis.
    • Application of the method to two types of multifunctional nanoparticles designed for photodynamic therapy and MRI-guided treatment.
    • Utilizing small-scale in vivo studies to gather pharmacokinetic data for model parameter estimation.

    Main Results:

    • The proposed model-based approach allows for rapid testing and selection of relevant PK model structures for subsequent studies.
    • Estimated model parameters provide valuable preliminary insights into tumor uptake, elimination rates, and residual storage of the tested nanomaterials.
    • The methodology facilitates the optimization of in vivo study protocols, including the duration of MRI sessions, in line with ethical 3Rs principles.

    Conclusions:

    • This model-based pre-characterization method accelerates the pharmacokinetic assessment of multifunctional nanomaterials in early-stage research.
    • It offers a pathway to more efficient and ethically compliant preclinical nanomedicine development by optimizing study designs.
    • The approach provides accurate enough parameter estimates for preliminary comparisons and informed decision-making in nanomedicine research.